Novartis Ag (NVS) Short term Debt (2016 - 2025)
Historic Short term Debt for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $5.6 billion.
- Novartis Ag's Short term Debt fell 3194.85% to $5.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.6 billion, marking a year-over-year decrease of 3194.85%. This contributed to the annual value of $5.6 billion for FY2025, which is 3194.85% down from last year.
- According to the latest figures from Q4 2025, Novartis Ag's Short term Debt is $5.6 billion, which was down 3194.85% from $7.5 billion recorded in Q3 2025.
- Novartis Ag's 5-year Short term Debt high stood at $10.2 billion for Q1 2021, and its period low was $5.5 billion during Q3 2023.
- Moreover, its 5-year median value for Short term Debt was $7.3 billion (2022), whereas its average is $7.4 billion.
- As far as peak fluctuations go, Novartis Ag's Short term Debt plummeted by 3566.68% in 2021, and later surged by 3331.17% in 2024.
- Quarter analysis of 5 years shows Novartis Ag's Short term Debt stood at $6.3 billion in 2021, then decreased by 5.78% to $5.9 billion in 2022, then rose by 4.11% to $6.2 billion in 2023, then skyrocketed by 33.31% to $8.2 billion in 2024, then tumbled by 31.95% to $5.6 billion in 2025.
- Its Short term Debt was $5.6 billion in Q4 2025, compared to $7.5 billion in Q3 2025 and $8.3 billion in Q2 2025.